Acquiring Advances in the Treatment of aTTP

<p>Jade L. Kutzke, Pharm.D., (<a href='https://twitter.com/kutzke_jade'>@kutzke_jade</a>) summarizes the pathophysiology of acquired thrombotic thrombocytopenic purpura, outlines the current aTTP treatment pathway and identifies caplacizumab’s role in the current treatment approach of aTTP.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>